NYSE:ABBVBiotechs
Assessing AbbVie's Valuation After Rinvoq’s Positive Phase 3 Results in Severe Alopecia Areata
AbbVie (ABBV) has just announced positive topline results from the second pivotal Phase 3 study for upadacitinib, its immunology drug marketed as Rinvoq, in treating severe alopecia areata. Both the 15 mg and 30 mg doses achieved the primary endpoint, with patients seeing meaningful scalp hair regrowth compared to placebo. As the company works to reinforce its immunology portfolio while older drugs face competitive threats, this kind of data can attract investors’ attention and prompt a...